Neurona Therapeutics, Inc.

Based in California, US, and founded in 2014 by co-founder and CEO Cory R. Nicholas, Neurona Therapeutics, Inc. is a clinical-stage biotherapeutics company that focuses on the development of cell-based therapeutics and treatment devices for neurological diseases and disorders. The company raised venture funding from Ysios Capital Partners.

In June 2026, UCB S. A. acquired Neurona Therapeutics, Inc. from Schroders Capital, Spur Capital, Alexandria Venture Investments, The Column Group, Viking Global Investors, Ysios Capital Partners, Fidelity Investments, Sphera Fund Management, Cormorant Asset Management, Ironfire Ventures, UC Ventures, LYFE Capital, UCB Ventures, Soleus Capital, The National Institutes of Health, Symbiosis Capital Management, Berkeley Frontier Fund, and YK Bioventures for an upfront payment of USD 650 million and will receive additional payment of USD 500 million upon achieving milestones.

The company specializes in developing neural cell therapies for chronic neurological disorders. The company’s primary product, NRTX-1001, consists of inhibitory GABAergic interneurons derived from pluripotent stem cells. NRTX-1001 is also being studied for its potential benefits in Alzheimer's disease by repairing neural activity and improving cognition. This therapy addresses drug-resistant focal epilepsy by enhancing GABAergic inhibition to reduce seizure activity.

  The acquisition enables UCB to add Neurona’s NRTX-1001 neuronal cell therapy to its epilepsy portfolio, expanding into regenerative medicine and advancing development of disease‑modifying treatments for drug‑resistant epilepsy.